These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 16126736

  • 1. A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance.
    Advani R, Lum BL, Fisher GA, Halsey J, Chin DL, Jacobs CD, Sikic BI.
    Ann Oncol; 2005 Dec; 16(12):1968-73. PubMed ID: 16126736
    [Abstract] [Full Text] [Related]

  • 2. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.
    Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, Sikic BI.
    Clin Cancer Res; 2001 May; 7(5):1221-9. PubMed ID: 11350887
    [Abstract] [Full Text] [Related]

  • 3. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
    Patnaik A, Warner E, Michael M, Egorin MJ, Moore MJ, Siu LL, Fracasso PM, Rivkin S, Kerr I, Litchman M, Oza AM.
    J Clin Oncol; 2000 Nov 01; 18(21):3677-89. PubMed ID: 11054441
    [Abstract] [Full Text] [Related]

  • 4. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
    Baekelandt M, Lehne G, Tropé CG, Szántó I, Pfeiffer P, Gustavssson B, Kristensen GB.
    J Clin Oncol; 2001 Jun 15; 19(12):2983-93. PubMed ID: 11408493
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.
    Fracasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP.
    J Clin Oncol; 2001 Jun 15; 19(12):2975-82. PubMed ID: 11408492
    [Abstract] [Full Text] [Related]

  • 6. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
    Fracasso PM, Westervelt P, Fears CL, Rosen DM, Zuhowski EG, Cazenave LA, Litchman M, Egorin MJ.
    J Clin Oncol; 2000 Mar 15; 18(5):1124-34. PubMed ID: 10694566
    [Abstract] [Full Text] [Related]

  • 7. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.
    Krishna R, St-Louis M, Mayer LD.
    Int J Cancer; 2000 Jan 01; 85(1):131-41. PubMed ID: 10585596
    [Abstract] [Full Text] [Related]

  • 8. Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance.
    Minami H, Ohtsu T, Fujii H, Igarashi T, Itoh K, Uchiyama-Kokubu N, Aizawa T, Watanabe T, Uda Y, Tanigawara Y, Sasaki Y.
    Jpn J Cancer Res; 2001 Feb 01; 92(2):220-30. PubMed ID: 11223552
    [Abstract] [Full Text] [Related]

  • 9. Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.
    Bajelan E, Haeri A, Vali AM, Ostad SN, Dadashzadeh S.
    J Pharm Pharm Sci; 2012 Feb 01; 15(4):568-82. PubMed ID: 23106959
    [Abstract] [Full Text] [Related]

  • 10. A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group.
    Carlson RW, O'Neill AM, Goldstein LJ, Sikic BI, Abramson N, Stewart JA, Davidson NE, Wood WC, Eastern Cooperative Oncology Group.
    Cancer Invest; 2006 Nov 01; 24(7):677-81. PubMed ID: 17118777
    [Abstract] [Full Text] [Related]

  • 11. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
    Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, Bates S.
    J Clin Oncol; 2001 Feb 01; 19(3):832-42. PubMed ID: 11157037
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.
    Fracasso PM, Blum KA, Ma MK, Tan BR, Wright LP, Goodner SA, Fears CL, Hou W, Arquette MA, Picus J, Denes A, Mortimer JE, Ratner L, Ivy SP, McLeod HL.
    Br J Cancer; 2005 Jul 11; 93(1):46-53. PubMed ID: 15942626
    [Abstract] [Full Text] [Related]

  • 13. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion.
    Krishna R, McIntosh N, Riggs KW, Mayer LD.
    Clin Cancer Res; 1999 Oct 11; 5(10):2939-47. PubMed ID: 10537363
    [Abstract] [Full Text] [Related]

  • 14. Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
    Sonneveld P, Burnett A, Vossebeld P, Ben-Am M, Rosenkranz G, Pfister C, Verhoef G, Dekker A, Ossenkoppele G, Ferrant C, Yin L, Gratwohl A, Kovacsovics T, Vellenga E, Capdeville R, Löwenberg B.
    Hematol J; 2000 Oct 11; 1(6):411-21. PubMed ID: 11920222
    [Abstract] [Full Text] [Related]

  • 15. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
    Mavroudis D, Kouroussis Ch, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Samonis G, Georgoulias V.
    Oncology; 2002 Oct 11; 62(3):216-22. PubMed ID: 12065868
    [Abstract] [Full Text] [Related]

  • 16. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL, Lin CH, Chao TY, Kao WY, Wang CH, Hsieh RK, Hwang WS.
    Cancer Chemother Pharmacol; 2008 Apr 11; 61(5):847-53. PubMed ID: 17609947
    [Abstract] [Full Text] [Related]

  • 17. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
    Lhommé C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, Baekelandt MM, Gordon AN, Fracasso PM, Mietlowski WL, Jones GJ, Dugan MH.
    J Clin Oncol; 2008 Jun 01; 26(16):2674-82. PubMed ID: 18509179
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
    Androulakis N, Kouroussis C, Mavroudis D, Kakolyris S, Souglakos J, Agelaki S, Kalbakis K, Malas K, Pallis A, Samonis G, Georgoulias V.
    Eur J Cancer; 2002 Oct 01; 38(15):1992-7. PubMed ID: 12376203
    [Abstract] [Full Text] [Related]

  • 19. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
    Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, Sonneveld P, Greipp PR.
    Cancer; 2006 Feb 15; 106(4):830-8. PubMed ID: 16419071
    [Abstract] [Full Text] [Related]

  • 20. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
    Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN.
    Ann Oncol; 1999 Apr 15; 10(4):403-11. PubMed ID: 10370782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.